secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2024-01-03T23:59:59+00:00
Accession:  0001104659-24-000571
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada Therapeutics promotes COO Nathan Dowden to President, effective Jan 1, 2024
--------------------------------------------------------------------------------

- Nathan J. Dowden promoted to President, retains COO role; Dipal Doshi continues as CEO.
- Salary increased to $480,000/year; target bonus raised to 45%.
- Granted 60,000 RSUs vesting 50% on 2nd anniversary and 50% on 3rd anniversary.
- Dowden has served as COO since Nov 2019 and has 30 years healthcare sector experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000110465924000571/0001104659-24-000571-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000110465924000571/tm241489d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-000571

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer